Exelixis Inc. (EXEL) Jumped After FDA Grants Priority Review

Exelixis Inc. (EXEL) announced Monday morning that its Phase 3 trial of cabozantinib in patients with advanced hepatocellular carcinoma met its primary endpoint.

from RTT - Before the Bell http://ift.tt/2ihjXFq
via IFTTT